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Abstract
Background: Melioidosis is a problem in the developing tropical regions of Southeast Asia and Northern Australia where the
the Gram negative saprophytic bacillus Burkholderia pseudomallei is endemic with the risk of fulminant septicaemia. While
diabetes mellitus is a well-established risk factor for melioidiosis, little is known if specific hypoglycemic agents may
differentially influence the susceptibility and clinical course of infection with B. pseudomallei (Bp).
Methodology/Principal Findings: In this cohort study, patients with pre-existing diabetes and melioidosis were
retrospectively studied. Outcome measures: mortality, length of stay and development of complications (namely
hypotension, intubation, renal failure and septicaemia) were studied in relation to prior diabetic treatment regimen.
Peripheral blood mononuclear cells (PBMC) from diabetic patients and healthy PBMC primed with metformin, glyburide and
insulin were stimulated with purified Bp antigens in vitro. Immune response and specific immune pathway mediators were
studied to relate to the clinical findings mechanistically. Of 74 subjects, 44 (57.9%) had sulphonylurea-containing diabetic
regimens. Patient receiving sulphonylureas had more severe septic complications (47.7% versus 16.7% p= 0.006), in
particular, hypotension requiring intropes (p = 0.005). There was also a trend towards increased mortality in sulphonylurea-
users (15.9% versus 3.3% p= 0.08). In-vitro, glyburide suppressed inflammatory cytokine production in a dose-dependent
manner. An effect of the drug was the induction of IL-1R-associated kinase-M at the level of mRNA transcription.
Conclusion/Significance: Sulphonylurea treatment results in suppression of host inflammatory response and may put
patients at higher risk for adverse outcomes in melioidosis.
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Introduction
Melioidosis is an environmental saprophyte endemic in tropical
regions. The infection is caused by the Gram negative saprophytic
bacillus Burkholderia pseudomallei found commonly in environmental
soil and surface water [1]. Clinical presentations of melioidosis
include bacteremia, abscesses in any organ systems, pneumonia or
soft tissue infection. The clinical course can be mild and chronic
through to fulminant leading to septic shock and death [2].
Diabetes mellitus is a well-established risk factor for suscepti-
bility to melioidosis [3,4]. Approximately 50% of patients
presenting with melioidosis are diabetics, the majority of whom
are already receiving anti-diabetic therapy. However little is
known if specific hypoglycemic agents, by themselves, may
differentially influence the susceptibility and clinical course of
infection with B. pseudomallei. This is important in light of recent
knowledge that sulphonylureas (glyburide) and the biguanides
(metformin) may possess modulating capabilities on host immune
response [5,6]. It is known that the activation of host immune
defence and the elaboration of inflammatory cytokines against the
pathogen is requisite [7,8] but opinion on the optimal cytokine
milieu for facilitating an effective host response during melioidosis
remains unclear [9,10].
Hence we aim to study whether commonly prescribed anti-
diabetic medications, in particular the sulphonylureas by virtue
of their ascribed immunomodulating potential, may influence
outcomes in melioidosis. Consequently, we also will attempt to
underline the mechanisms by which the specified drug may
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The study was conducted at two of Singapore’s largest hospitals,
the National University Hospital and the Tan Tock Seng Hospital,
each with more than1000-beds capacity. We identified patients
diagnosed with melioidosis between January 2001 to December
2010 from the integrated hospital electronic medical record
systems. A total of 116 such patients were identified, of which 15
subjects (12.9%) did not have diabetes by history and laboratory
investigation, while 27 subjects (23.3%) were newly diagnosed
diabetics upon presentation with melioidosis. The remaining 74
patients (63.8%) had pre-existing type II diabetes and receiving
medication prior to presenting with melioidosis and this was the
study cohort being analysed.
All patients received the recommended melioidosis treatment
regimen consisting of an initial intensive therapy consisting of
either ceftazidime, meropenem or imipenem intravenously for at
least 2 weeks, followed by a prolonged oral eradication phase
consisting of a combination of 2 oral agents from the 3 antibiotics:
trimethoprim-sulfamethoxazole (TMP-SMX), amoxicillin-clavula-
nate, doxycycline for at least 10 weeks [11]. Trimethoprim-
sulfamethoxazole was the backbone of the 2-drug eradication
regimen unless there were drug tolerance issues with individual
patients. The patients were followed up for at least 12 weeks.
Records of pre-existing diabetic medications were obtained from
clinical notes and/or verified from computerised outpatient
pharmacy archives. Most of the glycosylated haemoglobin
(HbA1c) levels were measured upon admission to hospital with
melioidosis. When this was not available, the last known HbA1c
level (up to 3 months prior presentation) was traced through
electronic outpatient records. The primary outcome measure was
mortality. The secondary outcome measures included length of
hospital stay and measures of disease severity, namely: (i)
hypotension requiring the infusion of inotropes (ii) respiratory
distress requiring mechanical ventilation (iii) renal impairment
with need for renal replacement therapy (iv) septicaemia as per
defined by the Surviving Sepsis Campaign Guidelines [12].
Reagents
The Toll like receptor (TLR) 4 ligand lipopolysaccharide (LPS-
EK Ultrapure, Escherichia coli serotype K-12) was purchased from
Invivogen (San Diego, CA). Metformin (a biguanide), glyburide (a
sulphonylurea) and human recombinant insulin were purchased
from Sigma-Aldrich (Singapore) and re-suspended in DMSO. The
antibodies ERK 1&2 (H-72) and p-ERK (E-4) were from Santa
Cruz Biotechnology, Inc (Dallas, TX).
Preparation of purified Bp antigen
Overnight culture of B. pseudomallei, Bp22, was inoculated
into LB broth (Difco Laboratories, Detroit, Michigan) and
incubated for 4 h at 37uC until an OD600 reading of 0.8–1.0.
The bacteria was pelleted at 4000 g for 10 min and washed
twice with 1X phosphate buffer saline (PBS), prior to
reconstitution in 1X PBS containing 0.2 mg/ml leupeptin
(Sigma-Aldrich, St Louis, MO), 0.2 mg/ml pepstatin A (Sigma-
Aldrich, St Louis, MO) and 2.5 Kunitz units of DNase I
(Sigma-Aldrich, St Louis, MO). To extract bacterial proteins,
the suspension was loaded into lysing Matrix B tubes (MP
Biochemicals, Solon, OH), and three rounds of homogeniza-
tion was performed using Fastprep instrument (MP Biochem-
icals, Solon, OH) at a speed of 6 m/s for 30 s with a pause of
10–15 min in between for cooling. The bacterial lysate was
centrifuged at 13000 g for 2 min, and passed through 0.22 mm
filter unit (Merck Millipore, Billerica, MA) to remove any live
bacteria. The supernatant was further purified and concen-
trated using Amicon Ultra-15 centrifugal units with 10 kDa
nominal molecular weight limit (NMWL) membrane (Merck
Millipore, Billerica, MA). The final purified Bp antigen were
recovered in 1XPBS, quantified by BCA protein assay kit
(Pierce Biotechnology, Rockford, IL) and used for further
stimulation experiments.
In-vitro stimulation assays
Separation and stimulation of peripheral blood mononuclear
cells (PBMC) from healthy volunteers and diabetic patients was
performed as previously described [13]. Blood was drawn into
sodium heparin tubes (BD Vacutainer Franklin Lakes, NJ) after
informed consent. PBMC were isolated by density centrifuga-
tion on Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Swe-
den). Cells were washed, counted and adjusted to 56106 cells/
mL in culture medium (RPMI 1640 DM supplemented with
gentamicin, L-glutamine, and sodium pyruvate). Stimulation
assays were performed in 96-well round-bottom plates using
100 ml of PBMC with the various stimuli and drugs to a total
volume of 200 ml per well. PBMC were pre-incubated with
metformin, glyburide, insulin or control media for 1 hour after
which purified Bp antigen was added. After 24 h or 48 h of
incubation in humidified atmosphere (5% CO2) at 37uC, the
supernatants were collected and stored at 220uC until further
assay.
Cytokine assay
Interleukin(IL)-6, IL-10, IL-1b, tumour necrosis factor-alpha
(TNF-a) and interferon- gamma (IFN-c) were measured by
commercial ELISA kit according to the instructions of the
manufacturer (eBioscience, San Diego, CA). Detection limits were
20 pg/ml (IL-1b, TNF-a and IFN-c) and 10 pg/ml (for IL-6 and
IL-10) respectively.
Western blot
PBMCs from healthy volunteers were treated with glyburide,
metformin, insulin and the carrier medium (DMSO) for 1 h,
followed by stimulation with purified Bp antigen for 30 mins.
Whole-cell lysates were prepared in RIPA buffer and protein
content was determined by the Bradford assay (Bio-Rad). 25 mg of
Author Summary
Melioidosis is a problem in the developing tropical regions
of Southeast Asia and Northern Australia where the Gram
negative bacillus Burkholderia pseudomallei can cause life-
threatening infection. Diabetes mellitus is a recognised risk
factor for melioidiosis; however little is known if commonly
used anti-diabetic drugs may affect the clinical course of
the disease. In this study, we found that patients who were
receiving sulphonylureas for diabetic treatment had more
severe septic complications requiring intensive care as well
as increased risk of deaths. This may be attributable to the
capacity of sulphonylureas in modulating the host
immune response. We highlight caution in the prescription
of this class of drug, which is popular due to its low cost
and easy availability, especially in melioidosis-endemic
tropical regions.
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lysates were electrophoresed on 10% polyacrylamide gels and
transferred to polyvinylidene difluoride membranes. After blocking
in 5% non-fat dry milk, the membranes were incubated with p-
ERK (sc-7383), p-JNK (#4668) or p-p38 (#9215) primary
antibodies. Horseradish peroxidase-conjugated secondary anti-
body was used and immunoreactive proteins were visualized with
chemiluminescence detection substrate (Pierce). The membranes
were stripped and re-probed for total ERK (sc-292838), JNK
(#9252) and p38 (#9215). Western blot was also performed for
MyD88 (sc-11356). Beta-actin (sc-47778) was used as the loading
control. Antibodies from Santa Cruz Biotechnology or Cell
Signaling were used.
Flow cytometry
PBMC were incubated with glyburide, metformin, insulin and
the carrier medium (DMSO) for 2 h prior to stimulation with
purified Bp antigen for 30 minutes. Following stimulation, cells
were washed twice with 1XPBS supplemented with 0.2% (w/v)
BSA and stained with anti-CD14-V450 antibody (BD Biosciences,
San Jose, CA). Cells were then fixed with BD Cytofix (BD
Biosciences, San Jose, CA) and permeabilized using Perm III
buffer (BD Biosciences, San Jose, CA) for 30 minutes. The
permeabilized cells were stained with mouse anti- p-ERK1/2
antibody (BD Biosciences, San Jose, CA), mouse anti- phospho-
JNK antibody (Cell signaling Technology, Danvers, MA) and goat
anti-IRAK-M antibody (Santa Cruz Biotechnology, Dallas, TX).
For cells stained with unlabelled goat anti-IRAK-M antibody,
secondary labeling with donkey anti-goat-FITC antibody (Santa
Cruz Biotechnology, Dallas, TX) was carried out. Stained
cells were then analyzed on FACSCanto flow cytometer (BD
Biosciences, San Jose, CA) and data analysis was performed using
Flow Jo software (version 7.6.5) (Tree Star, Ashland, OR).
Quantitative PCR
The expressions of interleukin-1 receptor-associated kinase-
1(IRAK-1) and interleukin-1 receptor-associated kinase-M (IRAK-
M) in PBMC primed with glyburide, metformin, insulin and
control medium were determined. RNA was extracted from 107
PBMC by using 1 ml TRIzol reagent (Sigma, St. Louis, MO).
Subsequently, 200 ml chloroform and 500 ml 2-propanol were used
to separate the RNA from DNA and proteins. After washing with
75% ethanol, the dry RNA was dissolved in 50 ml of diethylpyr-
ocarbonate (DEPC) water. To obtain cDNA, we reverse-
transcribed 1 mg DNase-treated total RNA with oligo(dT) primers
(0.01 mg/ml) in a reverse transcription-PCR mixture with a total
volume of 20 ml. Quantitative PCR was performed using the Bio-
Rad iCycler and SYBR Green. The following primers were used
(59-39): GTACATCAAGACGGGAAGGC (forward) and AGT-
GTGCTCTGGGTGCTTCT (reverse) for IRAK-1, GTACAT-
CAGACAGGGGAAACTTT (forward) and GACATGAATC-
CAGGCCTCTC (reverse) for IRAK-M, and ATGAGTATG-
CCTGCCGTGTG (forward) and CCAAATGCGGCATCTT-
CAAC (reverse) for b2 microglobulin (B2M) [9]. Quantification of
the PCR signals for each sample was performed by comparing the
cycle threshold values, in duplicate, for the gene of interest with
the cycle threshold values for the B2M as housekeeping gene. All
Table 1. Baseline demographics of melioidosis patients on diabetic therapy.
Sulphonylurea (N=44) Without Sulphonylurea (N=30) P value
Gender
Male 39 (88.6%) 24 (80.0%) 0.336
Female 5 (11.4%) 6 (20.0%)
Median age 58.2 56.5 0.536
Immunocompromised state 2 (4.5%) 4 (13.3%) 0.215
Statin use 22 (50.0%) 10 (33.3%) 0.155
HbA1c# 9.0062.30 9.5962.64 0.353
Serum creatinine (mmol/L) 1826200 2016281 0.750
Bp culture positive* 34 (77.3%) 26 (86.7%) 0.377
Concurrent diabetic medication
Metformin 23 (52.3%) 14 (46.7%) 0.848
Insulin 3 (6.8%) 18 (60.0%) 0.001
Thiazolidinedione 1 (2.3%) 2 (6.7%) 0.562
a-glucosidase inhibitor 9 (20.5%) 0 (0%) 0.010
Complications
Hypotension (inotropes) 13 (29.5%) 1 (3.3%) 0.005
Intubation 9 (20.5%) 2 (6.7%) 0.182
Renal Failure 8 (18.2%) 2 (6.7%) 0.187
Septicaemia 9 (20.5%) 3 (10.0%) 0.339
Any (above) complications 21 (47.7%) 5 (16.7%) 0.006
Length of stay (days) 27.7 21.5 0.168
Mortality 7 (15.9%) 1 (3.3%) 0.080
#10 (of 44) patients from the sulphonylurea group and 3 (of 30) patients from the no-sulphonylurea group had no recent HbA1c measurements available.
* Burkholderia pseudomallei culture positive. Other cases were diagnosed by positive melioidosis serology .1/64 titres.
doi:10.1371/journal.pntd.0002795.t001
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Figure 1. (A–D) Peripheral blood mononuclear cells (PBMC) from healthy donors were incubated with metformin, glyburide or
insulin at the indicated doses (0.0001–0.01 mg/mL or control media) for an hour after which purified Bp antigen (1 mg/mL) was
added for stimulation. (E) PBMC from diabetic patients receiving sulphonylurea (SU)-containing regimen (n = 9) versus those not on a non-SU
Sulphonylurea and Severe Disease in Melioidosis
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primers were validated according to the protocol. Mean relative
mRNA expression was calculated using Pfaffl method. Values are
expressed as a ratio of fold increase to mRNA levels of unprimed
cells.
Statistical analysis
The SPSS version 20.0 statistical software package was used to
perform the calculations. In the cohort study, the differences
between patient groups were analyzed using the chi-squared test
or Fisher exact probability where appropriate, for categorical
variables and the t-test for continuous variables. Adjustments for
the effect of HbA1c and diabetic drug usage on outcome measures
were performed using binary logistic regression. For the in-vitro
experiments, results were pooled from at least 3 sets of experiments
and analyzed, unless otherwise specified. The cytokine data was
presented as mean6standard error of the means (SEM). The
differences in cytokine production were tested using Mann-
Whitney U test. The level of significance was set at p,0.05.
Ethics statement
Ethics approval for the conduct of the above study had been
attained through the Domain Specific Review Boards, National
Healthcare Group, Singapore (no. 2012/00596 and no. 2012/
00949). Adult study subjects had provided written informed
consent to participate in the study. There were no study subjects
under the age of 21 years old.
Results
Sulphonylurea usage was associated with increased in-
patient complications during melioidosis
Of the 74 subjects with pre-existing diabetes on treatment and
melioidosis, 44 (57.9%) were taking a sulphonylurea group drug
either alone or in combination with other diabetic medications.
The demographics and outcomes of this group of patients were
studied against patients who did not receive sulphonylureas as part
of their diabetic drug regimen. As described in Table 1, the
background characteristics between the 2 groups of patients
including immune status and renal function were similar.
Glycaemic control as judged by their most recentHbA1c sugar
control was similar between both groups (9.00 versus 9.59,
p = 0.353).
However, patient receiving sulphonylurea-containing regi-
mens had higher incidence of secondary end points indicating
severity (47.7% versus 16.7%, p = 0.006). In particular,
melioidosis patients on sulphonylurea were more likely to be
hypotensive requiring inotropic support (29.5% versus 3.3%,
p = 0.005). The other analysed criteria showed increased
tendencies for mechanical ventilation and acute kidney injury
requiring renal replacement therapy. Similarly there was a
trend towards increased overall mortality in patients on
sulphonylurea (15.9% versus 3.3%, p = 0.080). After adjust-
ment for HbA1c, sulphonylurea usage remained a significant
predictor of development of severity manifestations (adjusted
odds ratio AOR 4.89, 95% confidence interval C.I. 1.37–17.5,
p = 0.015). Mortality was not significantly linked to prior
sulphonylurea exposure (AOR 4.48 95% C.I. 0.49–41.4,
p = 0.186) even after HbA1c correction.
Of note, concurrent insulin therapy was prescribed more in
diabetic regimens not containing sulphonylureas, and the converse
for a-glucosidase inhibitor. Melioidosis patients who had insulin as
part of their diabetic therapy had a lower incidence of severe
manifestations during infection (19.0% versus 41.5%, p= 0.104).
The use of metformin did not influence the clinical outcomes (data
not shown).
Sulphonylurea attenuates the inflammatory response
To specifically elucidate the influence of the respective diabetic
drugs on the immune response, PBMC from healthy volunteers
were primed with metformin, glyburide and insulin and then
stimulated with purified Bp antigen. Over a drug concentration
range of 0.001 mg/mL to 0.01 mg/mL, glyburide clearly
diminished the production of TNF-a, IL-1b and IL-10 in a
dose-dependent manner as compared to Bp control (in carrier
medium) (Figure 1A–D). Conversely, insulin had a tendency to
accentuate IL-1b response but this is only most evident at the dose
of 0.01 mg/mL (Figure 1B). Low dose metformin had a limited
effect in enhancing TNF-a, IL-1b and IFN-c production
(Figures 1A–C).
To further validate the above findings in the patient cohort,
PBMC from diabetic patients were stimulated with purified Bp
antigen. We found that patients who had sulphonylurea in
their treatment regimen for diabetes had a significantly weaker
IL-1b response (p = 0.04) as compared to patients who were on
non-sulphonylurea containing regimens. The attenuative
effects of sulphonylurea on the other cytokines in the patients
were suggestive but not significant (Figure 1E).
Sulphonylurea modulates cytokine mRNA transcription
Further to the above findings, we found that the attenuation of
cytokine production by glyburide was effected upstream at the
level of transcription. In the presence of glyburide, the IL-1b and
regimen (n = 13) were stimulated with purified Bp antigen. Cytokine responses were measured at 24 h for TNF-a and IL-1b and at 48 h for IL-10 and
IFN-c. The in-vitro data are cumulative results of at least 3 sets of experiments (n$9) and expressed as means6standard errors of the means (SEM). *
p,0.05 compared to the respective control (white bar) for (A–D) or between SU and non-SU group for (E).
doi:10.1371/journal.pntd.0002795.g001
Figure 2. IL-1b and TNF-a mRNA transcriptions were sup-
pressed in glyburide-primed PBMC as compared to metformin
and insulin treatment. * p,0.05 relative to the ratio of fold increase
in the mRNA levels of cells primed only in control media in absence of
diabetic drugs.
doi:10.1371/journal.pntd.0002795.g002
Sulphonylurea and Severe Disease in Melioidosis
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TNF-a mRNA transcription was significantly reduced. In
comparison, metformin and insulin induced minimal transcrip-
tional changes (Figure 2).
MyD88 and_JNK/ERK/p38 signaling are not influenced by
sulphonylurea
Because the suppressive effects induced by glyburide was
generally seen with IL-1b, TNF-a and IL-10 and possibly not
localized to a specific arm of the immune signaling pathway, we
decided it was logical to study first, the major upstream adaptor
molecule MyD88 and the mitogen-activated protein (MAP)
kinases JNK, ERK and p38 in the canonical innate signaling
pathways. However we found that the expression of MyD88, JNK,
ERK and p38 were not affected glyburide-treated cells
(Figures 3A–D).
Sulphonylurea modulates immune response though
IRAK-M
Recently it has been proposed that elevated expression of
IL-1R-associated kinase-M (IRAK-M), a regulator of the
inflammatory signaling pathway, was associated with adverse
outcome in septic melioidosis [9]. The role of IRAK-M in the
context of diabetes treatment and melioidosis, however, is not
known to date. We saw increased expression of IRAK-M
mRNA in glyburide-treated cells. The interleukin-1 receptor-
associated kinase 1 (IRAK-1) mRNA expression was not
affected (Figure 4A). The effects of insulin and metformin on
IRAK-M and IRAK-1 were limited. This was further
confirmed on flow cytometery showing increased IRAK-M
expression in monocytes exposed to glyburide (Figure 4B). This
up-regulation of IRAK-M expression reasonably accounts for
the immune suppressive effects induced by glyburide, and the
association with disease severity observed with sulphonylurea
use in melioidosis.
Discussion
During an infection the capacity of the host to mount an
appropriate immune and inflammatory response against the
pathogen is pivotal. In the context of recent reports that diabetic
medications like glyburide and metformin may possess inherent
immune modulating capabilities, at least in the in-vitro setting [5,6],
we felt that it was important to study this further in the clinical
context of melioidosis whereby diabetics are specifically predis-
posed to.
In this study, we found that the use of a sulphonylurea-
containing diabetes treatment regimen is linked to a more severe
clinical course especially hypotension during melioidosis. This
finding has implications for the large number of diabetics living in
melioidosis endemic regions, particularly Singapore, Thailand and
Northern Australia. The low cost of sulphonylureas, its availability
and its relatively wide therapeutic window contributes to the
popularity of the drug. While glycaemic control between the 2
treatment groups might have been a potential factor contributing
to the difference in outcomes, we have shown that HbA1c was not
a significant confounder of the results.
We showed that glyburide had the capacity to suppress cytokine
production. These effects were seen not only in-vitro in cells primed
with the drug, but also similarly demonstrated in diabetic patients
who were taking sulphonylureas. The importance of this latter
finding is to be highlighted in that the differences in cytokine
trends could still be elicited despite the numerous of confounders
like multiple co-morbidities and polypharmacy in the clinical
Figure 3. (A–D) Western blot from cell lysates of PBMC primed with diabetic drugs for 1 hour and then stimulated with purified Bp
antigen for 30 minutes. The membranes were stripped and re-probed for MyD88, total and phosphorylated (p-) JNK, ERK and p38. Beta-actin was
used as the loading control. Result is representative from 2 sets of experiment.
doi:10.1371/journal.pntd.0002795.g003
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cohort. The attenuative effect on cytokine production was exerted
at the level of mRNA transcription and one of the effects of
glyburide was through the enhancement of IRAK-M which
assumes a regulatory or inhibitory role in proinflammatory
cytokine production in the TLR/IL-1R signaling pathway though
inhibition of nuclear transcription factor NF-kappaB [14]. Con-
versely, IRAK-1 which up-regulates NF-kappaB, is suppressed.
These findings on the mechanistic action of glyburide are novel as
to date; glyburide is reported to act through the NALP3
inflammasome complex [5].
The response to infection by B. pseudomallei requires the host
defence to first mount a prompt and effective innate immune
Figure 4. (A) IRAK-M mRNA expression is elevated by glyburide. * p,0.05 relative to the ratio of fold increase in the mRNA levels of cells
primed only in control media in absence of diabetic drugs. (B) Flow cytometry of glyburide-treated PBMC showed increased expression of IRAK-M in
CD-14 positive monocytes following stimulation with purified Bp antigen. The cells were surface labeled with anti-CD14-V450 antibody,
permeabilized and then labeled with primary goat anti-IRAK-M antibody. Secondary labeling with donkey anti-goat-FITC antibody was performed
and cells were analyzed by flow cytometry. Result from a representative set of experiment is shown.
doi:10.1371/journal.pntd.0002795.g004
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response [7]. Results from our studies indicate that this capacity to
mount an inflammatory cytokine milieu is compromised in the
background presence of sulphonylureas in the body. This
hypothesis is supported by the recent finding that increased
IRAK-M with consequent immunosuppresion was associated with
poor outcome in melioidosis, though the specific aspect of diabetes
and drugs was not looked at in that study [9].
The findings of our study is in contrast to that by another group
[10], who had reported reduced mortality, hypotension and
respiratory failure with glyburide usage in melioidosis in Thailand.
The group had hypothesized that the inhibition of the inflamma-
some and the neutrophil-mediated inflammatory process by
glyburide might be beneficial in limiting sepsis-induced tissue
injury and organ damage. Conversely, it is imperative that the host
innate immunity be able to mount a robust inflammatory response
against the pathogen during the initial phase of infection. The
presence of sulphonylurea in the body compromises the immune
response as we have demonstrated. Furthermore, such modulation
of the IRAK complex as induced by sulphonylurea leads to
susceptibility to infections as can be seen in patients with these
genetic deficiencies [15]. In our smaller cohort of patients in
Singapore, we were able to document diabetic drug history from
our electronic records as well as the prescribed appropriate initial
intensive therapy for at least 2 weeks followed by oral eradication
therapy of at least 10 weeks as per recommended for melioidosis
[16]. While HbA1c was not captured in the Thai cohort, we had
sought to obtain the last known HbA1c of our patients and had
factored glycaemic control into our analysis to show that
sulphonylurea usage was an independent predictor of developing
severe disease in melioidosis.
In our study, the diabetic patients who were receiving insulin
tended not to be prescribed concurrent sulphonylurea. This was
expected as per prescribing practice in the management of
diabetes. Our data suggests that patients on insulin might have a
lower risk of severe septic manifestations of melioidosis. However
we are cautious in not over-interpreting these results at this point
as functionally, the immunomodulatory effects of insulin are not as
clearly evident as compared to the suppression of cytokines
induced by sulphonylurea. To validate these findings, the
mechanistic effects of insulin need to be elucidated further.
Diabetes mellitus remains the single most important risk factor
for development of melioidosis. We find here that a sulphonylurea-
containing diabetes treatment regimen suppresses the host
inflammatory response and puts patients at higher risk for adverse
outcomes. The implication of this finding may extend beyond
melioidosis to other Gram negative septicaemia. Against the
background of the popularity of sulphonylurea use in diabetes,
this study highlights caution in the prescription of this class of drug
especially in melioidosis-endemic regions.
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